Antiplatelet Therapy
Introduction to Ticagrelor
- Ticagrelor is an oral, reversibly binding P2Y12 receptor inhibitor with faster onset of action, more consistent platelet inhibition, and more rapid recovery of platelet function compared to clopidogrel, used primarily in acute coronary syndromes to prevent thrombotic cardiovascular events in patients with acute coronary syndromes, including NSTE-ACS and STEMI, as recommended by the American College of Cardiology 1, 2
Dosage and Administration
- The maintenance dose of ticagrelor is 90 mg twice daily, and it should be taken with low-dose aspirin (recommended dose 81 mg daily) for optimal efficacy, as recommended by the European Society of Cardiology and the American Heart Association 1, 3, 4, 5, 6
- A loading dose of 180 mg ticagrelor is recommended when switching from clopidogrel to ticagrelor in patients post stent placement, regardless of prior clopidogrel therapy, and clopidogrel should be discontinued immediately when ticagrelor is commenced, as recommended by the European Society of Cardiology 7
Efficacy and Safety
- Ticagrelor reduces stent thrombosis compared to clopidogrel, and is associated with a higher risk of non-CABG-related bleeding, and dyspnea occurs in up to 15% of patients, as reported in the PLATO trial 1, 8
- The PLATO trial demonstrated ticagrelor's superior efficacy compared to clopidogrel in 18,624 patients with acute coronary syndrome, with a primary composite endpoint (cardiovascular death, MI, or stroke) significantly reduced with ticagrelor (9.8% vs 11.7%, HR 0.84, p<0.001) 8
| Endpoint | Ticagrelor | Clopidogrel | HR (95% CI) | p-value |
|---|---|---|---|---|
| Cardiovascular death, MI, or stroke | 9.8% | 11.7% | 0.84 (0.77-0.92) | <0.001 |
- Ticagrelor increases the risk of bleeding, including fatal intracranial hemorrhage, compared with clopidogrel, with a warning from the American College of Cardiology, and the risk of bleeding must be weighed against the risk of thrombotic events for urgent procedures 3, 9
Comparison to Other Antiplatelet Agents
- Both ticagrelor and other P2Y12 inhibitors are more potent than clopidogrel and associated with a higher bleeding risk, as reported by the European Society of Cardiology and the American College of Cardiology 10, 7
- Combining multiple antiplatelet agents, such as ticagrelor and clopidogrel, increases bleeding risk, with moderate strength of evidence, as reported by the American College of Cardiology 5
Contraindications and Precautions
- Ticagrelor should be avoided in patients with previous intracranial hemorrhage, active pathological bleeding, or severe hepatic impairment, with a warning from the European Heart Journal and American College of Cardiology guidelines, and concomitant use of ticagrelor with strong CYP3A4 inhibitors or inducers may affect its pharmacokinetics, requiring dose adjustments and close monitoring 4, 5, 11, 12, 6, 13
Duration of Therapy
- P2Y12 inhibitor therapy, including ticagrelor, should be continued for at least 12 months for ACS patients with either bare metal stents (BMS) or drug-eluting stents (DES), as recommended by the European Society of Cardiology, the American Heart Association, and the Circulation guidelines 14, 4, 5, 15
- For patients receiving DES for non-ACS indications, a minimum of 12 months of P2Y12 inhibitor therapy is recommended, and for patients receiving BMS for non-ACS indications, a minimum of 1 month, ideally up to 12 months, of therapy is recommended, as stated in the Circulation and American College of Cardiology guidelines 4, 15
Monitoring and Discontinuation
- Patients on ticagrelor should be monitored for bleeding complications, which are more common with ticagrelor than clopidogrel, and for adverse effects such as dyspnea, bradycardia, and ventricular pauses, as recommended by the European Society of Cardiology and the American College of Cardiology guidelines 11, 8, 6
- Concomitant use of ticagrelor with statins requires monitoring for muscle pain, tenderness, weakness, and elevated creatine kinase levels, with specific dosing restrictions for simvastatin and lovastatin, as stated in the American College of Cardiology guidelines 13
- The American Heart Association recommends against discontinuing ticagrelor prematurely in ACS patients, as this significantly increases cardiovascular risk, with a Class I, Level of Evidence: B recommendation, and abrupt discontinuation of ticagrelor without appropriate coverage could theoretically increase thrombotic risk, with low strength of evidence 3, 5
- The European Society of Cardiology recommends discontinuing ticagrelor at least 5 days before elective procedures if surgery is needed while on both medications, and monitoring for bleeding complications, dyspnea, bradycardia, and ventricular pauses 7, 3, 4